BibTex RIS Cite

Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma

Year 2016, Volume: 3 Issue: 3, 151 - 2, 15.03.2016

Ali Eser Funda Pepedil Tanrikulu , Ayse Tulin Firatli Tuglular

Abstract

A 53-year-old patient who had a 7 year history of multiple myeloma was diagnosed with high risk myelodysplastic syndrome while on lenalidomide treatment. Progression to acute myeloid leukemia has occurred during the following 4 months. Like our case, secondary primary malignancies (SPMs) can rarely complicate treatment of multiple myeloma. Although possible association between SPMs in patients receiving lenalidomide can be attributed to previous melphalan use, potential SPM risk with lenalidomide cannot still be ruled out safely

 

Keywords

Multiple myeloma; Lenalidomide; Acute myeloid leukemia

References

  • Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121-5.
  • Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
  • McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
  • Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
  • Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012;119(12):2764-7.
  • Rossi AC, Mark TM, Jayabalan D, Christos PJ, Zafar F, Pekle K, et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). J Clin Oncol. 2011;29: abstr 8008.

Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma

Year 2016, Volume: 3 Issue: 3, 151 - 2, 15.03.2016

Ali Eser Funda Pepedil Tanrikulu , Ayse Tulin Firatli Tuglular

Abstract

References

  • Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121-5.
  • Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
  • McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
  • Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
  • Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012;119(12):2764-7.
  • Rossi AC, Mark TM, Jayabalan D, Christos PJ, Zafar F, Pekle K, et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). J Clin Oncol. 2011;29: abstr 8008.
There are 6 citations in total.

Details

Primary Language English
Journal Section Letter to Editor
Authors

Ali Eser This is me

Funda Pepedil Tanrikulu

Ayse Tulin Firatli Tuglular This is me

Publication Date March 15, 2016
Published in Issue Year 2016 Volume: 3 Issue: 3

Cite

APA Eser, A., Pepedil Tanrikulu, F., & Firatli Tuglular, A. T. (2016). Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Medical Science and Discovery, 3(3), 151-2. https://doi.org/10.17546/msd.84603
AMA Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT. Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Med Sci Discov. March 2016;3(3):151-2. doi:10.17546/msd.84603
Chicago Eser, Ali, Funda Pepedil Tanrikulu, and Ayse Tulin Firatli Tuglular. “Acute Myeloid Leukemia under Lenalidomide Therapy in a Patient With Multiple Myeloma”. Medical Science and Discovery 3, no. 3 (March 2016): 151-2. https://doi.org/10.17546/msd.84603.
EndNote Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT (March 1, 2016) Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Medical Science and Discovery 3 3 151–2.
IEEE A. Eser, F. Pepedil Tanrikulu, and A. T. Firatli Tuglular, “Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma”, Med Sci Discov, vol. 3, no. 3, pp. 151–2, 2016, doi: 10.17546/msd.84603.
ISNAD Eser, Ali et al. “Acute Myeloid Leukemia under Lenalidomide Therapy in a Patient With Multiple Myeloma”. Medical Science and Discovery 3/3 (March 2016), 151-2. https://doi.org/10.17546/msd.84603.
JAMA Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT. Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Med Sci Discov. 2016;3:151–2.
MLA Eser, Ali et al. “Acute Myeloid Leukemia under Lenalidomide Therapy in a Patient With Multiple Myeloma”. Medical Science and Discovery, vol. 3, no. 3, 2016, pp. 151-2, doi:10.17546/msd.84603.
Vancouver Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT. Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Med Sci Discov. 2016;3(3):151-2.
 Download Cover Image